2.9000 -0.03 (-1.02%)
After hours: 4:16PM EDT
|Bid||2.9200 x 2200|
|Ask||3.0500 x 27000|
|Day's Range||2.8800 - 3.0000|
|52 Week Range||1.2900 - 3.9800|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.17|
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
- ACH-4471 increased hemoglobin and nearly eliminated the need for transfusions in patients with PNH being treated with C5 inhibitor, eculizumab - BLUE BELL, Pa., May 17, 2019.
BLUE BELL, Pa., May 14, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) ), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.
Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.
Biotech stocks saw a reversal in sentiment as the week saw an earnings deluge from small-, micro- and nano-cap biotechs and some M&A activity . Here are some key catalysts for the unfolding week that should ...
The clinical-stage biotech didn't have any revenue in the first quarter. But it made progress in several key areas.
On a per-share basis, the New Haven, Connecticut-based company said it had a loss of 14 cents. The company's shares closed at $2.88. A year ago, they were trading at $3.67. _____ This story was generated ...
- PNH combo Phase 2 trial interim data to be presented May 17, 2019 -- C3G Phase 2 trials 24 patients enrolled as of May 2019 - - Next-generation ACH-5228 planned U.S. IND.
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.
Achillion (ACHN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Achillion (ACHN) achieves enrollment target in two mid-stage studies evaluating its lead candidate, ACH-4471 in C3G, a devastating disease affecting the kidney.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that it achieved threshold enrollment in the Phase 2 trials of ACH-4471 for patients with C3 glomerulopathy (C3G), a devastating disease affecting the kidney for which there is no approved therapy. ACH-4471 will be evaluated in the six-month blinded, placebo-controlled trial (11 patients) and the 12-month open-label trial (12 patients). “Enrolling our ACH-4471 Phase 2 trials is an important milestone for Achillion, and we would like to thank all of the patients, families, investigators and participating clinical trial sites for their outstanding contributions,” said Joe Truitt, President and Chief Executive Officer at Achillion.
Achillion (ACHN) achieves enrollment target in a mid-stage study evaluating its lead candidate, ACH-4471, in paroxysmal nocturnal hemoglobinuria, a rare life-threatening disease of the blood.
In the Phase 2 trial, patients with an inadequate response to eculizumab as monotherapy are being evaluated for increases in hemoglobin and reduced transfusions over 24-weeks. Early data released in December 2018 provided evidence that ACH-4471 in combination with eculizumab had a positive impact on patient hemoglobin and FACIT-fatigue scores while reducing transfusions, reticulocyte counts and LDH levels.
Achillion Pharmaceuticals, Inc.'s (NASDAQ:ACHN) most recent earnings announcement in December 2018 suggested company earnings became less negative compared to the previous year's level - great news for investors Today IRead More...
Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.
BLUE BELL, Pa., March 08, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and.
- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 -- Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting -- Next-generation.
A Connecticut biopharmaceutical company, with growth in its plans, has moved its executive offices and clinical operations to suburban Philadelphia. Achillion Pharmaceuticals of New Haven, Conn., has opened a 12,000-square-foot office in Blue Bell where the company has 30 employees and expects to add more. Joe Truitt, Achillion's president and CEO, said the move to Blue Bell was done with future hiring in mind.
NEW HAVEN, Conn., Feb. 21, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients.
NEW HAVEN, Conn., Feb. 19, 2019 -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients.
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Achillion Pharmaceuticals, Inc. (ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato to the position of Senior Vice President and Chief Financial Officer, effective immediately. Mr. Di Donato has over 20 years of financial and leadership experience and will assume responsibility for finance, accounting and treasury as well as continue to lead investor relations. “Brian joined the Achillion team in August 2018 and has already made significant contributions alongside the new management team as we accelerate our clinical programs and prepare for registrational trials,” commented Joseph Truitt, President and Chief Executive Officer of Achillion.